Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis Jan 27, 2025 07:00AM
Vanda Pharmaceuticals (VNDA) Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness May 15, 2024 08:45AM
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness May 15, 2024 08:45AM
Vanda Pharmaceuticals (VNDA) Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ Apr 22, 2024 07:14PM
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation Apr 22, 2024 07:13PM
View Older Stories

Feb 5, 2024 08:01AM Vanda Pharmaceuticals (VNDA) Announces FDA Update for supplemental NDA for HETLIOZ in the Treatment of Insomnia
Feb 5, 2024 08:00AM Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
Jan 31, 2024 09:01AM Vanda Pharmaceuticals (VNDA) Receives FDA Approval to Proceed with Investigational New Drug VTR-297
Jan 31, 2024 09:00AM Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Jan 25, 2024 10:05PM Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
Jan 23, 2024 09:16AM Vanda Pharmaceuticals (VNDA) Granted FDA Approval to Proceed with VCA-894A
Jan 23, 2024 09:15AM Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Jan 19, 2024 03:57PM Vanda Pharmaceuticals (VNDA) Says Federal Court Allows its Lawsuit to Proceed Against the U.S. FDA
Jan 19, 2024 03:56PM Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
Jan 17, 2024 03:47PM Vanda Pharmaceuticals (VNDA) announces publication of Efficacy and Safety of Iloperidone in Bipolar Mania
Jan 17, 2024 03:46PM Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
Jan 12, 2024 12:26PM Vanda Pharmaceuticals (VNDA) Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
Jan 12, 2024 12:21PM Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
Nov 8, 2023 04:01PM Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
Oct 20, 2023 07:00AM Vanda Pharmaceuticals (VNDA) Intends to Petition the U.S. Supreme Court in its HETLIOZ ANDA Litigation
Oct 20, 2023 07:00AM Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
Jul 27, 2023 04:01PM Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
Jul 20, 2023 04:30PM Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
Jun 5, 2023 07:00AM Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference
Jun 2, 2023 05:59AM Vanda Pharmaceuticals (VNDA) Announces Orphan Drug Designation Granted for VCA-894A
Jun 1, 2023 09:41PM Vanda Pharmaceuticals Announces Presentations at SLEEP 2023
Jun 1, 2023 09:31PM Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
May 25, 2023 07:00AM Vanda Pharmaceuticals (VNDA) Reports Results from a Phase III study of Tradipitant
May 25, 2023 07:00AM Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
May 10, 2023 02:27PM Vanda Pharmaceuticals (VNDA) Responds to Ruling in HETLIOZ ANDA Appeal
May 10, 2023 02:26PM Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal
May 4, 2023 06:00PM Vanda Pharmaceuticals Announces Presentations at DDW 2023
May 3, 2023 04:01PM Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
May 2, 2023 12:54PM Vanda Pharmaceuticals (VNDA) Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information
May 2, 2023 12:46PM Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information
Apr 27, 2023 06:00PM Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023
Mar 28, 2023 01:26PM Vanda Prevails in Jet Lag Litigation Against the FDA
Mar 17, 2023 07:02AM Vanda Pharmaceuticals (VNDA) Appoints Dr. Tage Honoré to its Board of Directors
Mar 17, 2023 07:00AM Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
Feb 8, 2023 04:01PM Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 1, 2023 06:30PM Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
Jan 6, 2023 09:00AM Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Dec 19, 2022 07:01AM Vanda Pharmaceuticals (VNDA) Reports Fanapt Shown Effective in Bipolar I Disorder in Phase III Clinical Study
Dec 19, 2022 07:00AM Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
Dec 16, 2022 02:55PM Vanda Pharmaceuticals (VNDA) Provides an Update to HETLIOZ ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch
Dec 16, 2022 02:54PM Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch
Dec 13, 2022 03:16PM Vanda Pharmaceuticals (VNDA) Responds to Ruling in HETLIOZ ANDA Litigation, Intends to Appeal
Dec 13, 2022 03:15PM Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation
Dec 2, 2022 07:03AM Vanda Pharmaceuticals (VNDA) Reports Results in Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety
Dec 2, 2022 07:00AM Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety
Nov 8, 2022 08:30PM Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
Nov 2, 2022 04:01PM Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results
Oct 26, 2022 06:00PM Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Oct 21, 2022 02:01PM Vanda Pharmaceuticals (VNDA) Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
Oct 21, 2022 02:00PM Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
View Older Stories